List of Tables
Table 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Gastric Cancer Methylation Screening
Table 3. Key Players of Esophageal Cancer Methylation Screening
Table 4. Key Players of Colorectal Cancer Methylation Screening
Table 5. Key Players of Lung Cancer Methylation Screening
Table 6. Key Players of Liver Cancer Methylation Screening
Table 7. Key Players of Other Cancer Screening
Table 8. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2019-2024)
Table 12. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2025-2030)
Table 14. Cell-Free Circulating Tumor DNA (ctDNA) Market Trends
Table 15. Cell-Free Circulating Tumor DNA (ctDNA) Market Drivers
Table 16. Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges
Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Market Restraints
Table 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players (2019-2024)
Table 20. Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2023)
Table 21. Ranking of Global Top Cell-Free Circulating Tumor DNA (ctDNA) Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Cell-Free Circulating Tumor DNA (ctDNA) Product Solution and Service
Table 25. Date of Enter into Cell-Free Circulating Tumor DNA (ctDNA) Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2019-2024)
Table 29. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2025-2030)
Table 31. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2019-2024)
Table 33. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2025-2030)
Table 35. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)
Table 50. Nexomics Company Detail
Table 51. Nexomics Business Overview
Table 52. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 53. Nexomics Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 54. Nexomics Recent Development
Table 55. Roche Company Detail
Table 56. Roche Business Overview
Table 57. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 58. Roche Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 59. Roche Recent Development
Table 60. ORIOMICS Company Detail
Table 61. ORIOMICS Business Overview
Table 62. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 63. ORIOMICS Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 64. ORIOMICS Recent Development
Table 65. Signatera Company Detail
Table 66. Signatera Business Overview
Table 67. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 68. Signatera Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 69. Signatera Recent Development
Table 70. Illumina Company Detail
Table 71. Illumina Business Overview
Table 72. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 73. Illumina Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 74. Illumina Recent Development
Table 75. Sysmex Corporation Company Detail
Table 76. Sysmex Corporation Business Overview
Table 77. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 78. Sysmex Corporation Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 79. Sysmex Corporation Recent Development
Table 80. Bio-Rad Company Detail
Table 81. Bio-Rad Business Overview
Table 82. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 83. Bio-Rad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 84. Bio-Rad Recent Development
Table 85. Biocartis Company Detail
Table 86. Biocartis Business Overview
Table 87. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 88. Biocartis Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 89. Biocartis Recent Development
Table 90. QIAGEN Company Detail
Table 91. QIAGEN Business Overview
Table 92. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 93. QIAGEN Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 94. QIAGEN Recent Development
Table 95. GuardantHealth Company Detail
Table 96. GuardantHealth Business Overview
Table 97. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 98. GuardantHealth Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 99. GuardantHealth Recent Development
Table 100. GSK plc Company Detail
Table 101. GSK plc Business Overview
Table 102. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 103. GSK plc Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 104. GSK plc Recent Development
Table 105. AstraZeneca Company Detail
Table 106. AstraZeneca Business Overview
Table 107. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 108. AstraZeneca Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 109. AstraZeneca Recent Development
Table 110. NeoGenomics Laboratories Company Detail
Table 111. NeoGenomics Laboratories Business Overview
Table 112. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 113. NeoGenomics Laboratories Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 114. NeoGenomics Laboratories Recent Development
Table 115. AmoyDx Company Detail
Table 116. AmoyDx Business Overview
Table 117. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 118. AmoyDx Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 119. AmoyDx Recent Development
Table 120. Annoroad Company Detail
Table 121. Annoroad Business Overview
Table 122. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 123. Annoroad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 124. Annoroad Recent Development
Table 125. Burning Rock Biotech Company Detail
Table 126. Burning Rock Biotech Business Overview
Table 127. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product
Table 128. Burning Rock Biotech Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)
Table 129. Burning Rock Biotech Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type: 2023 VS 2030
Figure 3. Gastric Cancer Methylation Screening Features
Figure 4. Esophageal Cancer Methylation Screening Features
Figure 5. Colorectal Cancer Methylation Screening Features
Figure 6. Lung Cancer Methylation Screening Features
Figure 7. Liver Cancer Methylation Screening Features
Figure 8. Other Cancer Screening Features
Figure 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application: 2023 VS 2030
Figure 11. Hospital Case Studies
Figure 12. Medical Center Case Studies
Figure 13. Laboratory Case Studies
Figure 14. Cell-Free Circulating Tumor DNA (ctDNA) Report Years Considered
Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region: 2023 VS 2030
Figure 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players in 2023
Figure 19. Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2023
Figure 21. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)
Figure 23. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)
Figure 27. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2019-2030)
Figure 35. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)
Figure 43. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)
Figure 47. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Nexomics Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 50. Roche Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 51. ORIOMICS Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 52. Signatera Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 53. Illumina Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 54. Sysmex Corporation Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 55. Bio-Rad Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 56. Biocartis Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 57. QIAGEN Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 58. GuardantHealth Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 59. GSK plc Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 60. AstraZeneca Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 61. NeoGenomics Laboratories Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 62. AmoyDx Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 63. Annoroad Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 64. Burning Rock Biotech Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed